Quality of life after autologous peripheral blood stem cell transplantation and high-dose chemotherapy in high-risk breast cancer patients

2Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: As long-term survivors of breast cancer after autologous peripheral blood stem cell transplantation (ASCT) are becoming more numerous, studies addressing the issue of long-term follow-up are necessary. In this study, we report on the quality of life (QOL) after ASCT and high-dose chemotherapy (HDCT). Patients and Methods: The QOL questionnaire version 3.0 by the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30 version 3.0) was filled in by patients and healthy controls at 5 time points. After ob-taining the results, we analyzed the correlation between QOL and the effect factors. Results: Some functions got significantly worse, and some symptoms got more serious after ASCT and HDCT. However, most of them improved with time and were comparable to the healthy controls after 5 years. QOL was in part related to age, tumor characteristics, educational level, marriage status, and income. Conclusions: Evaluating QOL allows medical workers to fully understand a patient's state of health, and aid the estimation and selection of clinical treatment methods as well as improve recovery. © 2009 S. Karger GmbH, Freiburg.

Cite

CITATION STYLE

APA

Zhang, L., Tong, Z., Li, S., Ren, X., Ren, B., Wang, X., … He, L. (2009). Quality of life after autologous peripheral blood stem cell transplantation and high-dose chemotherapy in high-risk breast cancer patients. Breast Care, 4(6), 379–386. https://doi.org/10.1159/000266759

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free